|
|
|
| Home |  | Corporate Social Responsibility |
|
|
GSK in the Community
 
GlaxoSmithKline (GSK) strives to be a valued corporate citizen no matter where it does business. We have always shown strong commitment and support for public health and awareness initiatives and championed many social causes.
At GSK, we know that part of being a successful and sustainable business is fulfilling our social responsibilities, making our company more responsive, more flexible and more open to society’s expectations. We are working towards improving access to our medicines, enhancing research opportunities for neglected tropical diseases, raising the ethical standards for conducting our research and business activities, and being more open and transparent in the way we run our business. We are adapting our business model to adopt a more open approach to R&D for diseases of the developing world.
GSK has put many of its important resources –including a pool of patents, research ‘know-how’ and technology assets –into an open ‘knowledge pool.’ Researchers outside of GSK can now use this information, which will hopefully stimulate cutting-edge research on medicines for neglected diseases, including malaria. The knowledge pool is now being administered by the not-for-profit BIO Ventures for Global Health.
As part of this initiative, GSK announced in January 2010, the establishment of the first ever ‘Open Lab’ to act as an engine room of scientific innovation for neglected tropical diseases. GSK has created capacity for up to 60 scientists from around the world to have access to the ‘Open Lab’, which will be based at the company’s research centre at the Tres Cantos Campus, Spain. In the ‘Open Lab’, scientists will be encouraged to tap into the expertise, knowledge and infrastructure of the company, while pursuing their own projects as part of an integrated drug discovery team.
In June 2010 GSK was ranked top in the ‘Access to Medicine Index’ for the second successive time. The Access to Medicine Index is a ranking of world´s largest pharmaceutical companies on their efforts to increase access to medicine for societies in need. GSK also announced the formation of a new operating unit dedicated to expanding access to medicines for people living in Least Developed Countries (LDCs) in 2010.
GSK believes in working as partners with under-served communities in the developed and developing world supporting programmes that are innovative, sustainable and bring real benefit to these communities.
Our programmes are organised into global, regional and local activities.
|